Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum

When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with a planned invasive strategy, kidney function should not interfere in this decision. 

The main findings of this study were that prasugrel has lower risk of all cause death, MI or stroke, and also had a similar risk of bleeding compared against ticagrelor. These findings were consistent with those of low and intermediate risk patients or high glomerular filtration. 

These findings were presented during the ESC 2021 scientific sessions and were simultaneously published in JACC: Cardiovascular Interventions.

Patients with altered kidney function are challenging for multiple reasons: on the one hand, they present higher ischemic risk and on the one hand, a higher risk of bleeding, given drug pharmacokinetics. 

For this analysis, the authors divided 4,012 participants according to glomerular filtration into 3 groups: low (<60 mL/min/1.73; m2; 760 patients), intermediate (60 to 90 mL/min/1.73 m2; 1968 patients) and high (>90 mL/min/1.73 m2; 1284 patients).

As expected, the worse the glomerular filtration, the bigger the number of events, both ischemic and hemorrhagic.  

However, this did not affect the relative efficacy of prasugrel. Moreover, its biggest advantage was in patients with worse glomerular filtration. 


Read also: ESC 2021 | TOMAHAWK: Angiography After Resuscitated Patients from Out-Of-Hospital Cardiac Arrest with No ST Elevation.


Specifically, in this last subgroup, the rate of all cause death, MI or stroke was significantly higher in patients receiving ticagrelor vs prasugrel (20.5% vs 14.7%; HR 1.47; CI 95% 1.04 to 2.08), with no cost in bleeding BARC 3-5 (10.4% vs 8.4%; HR 1.24; CI 95% 0.73-2.09).

After a few years of absolute dominion of ticagrelor, several studies have slowly brought back prasugrel and clopidogrel to the current clinical arena.  

Original Title: Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate. 

Reference: Wöhrle J. J Am Coll Cardiol Intv. 2021; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...